Mandate

Vinge advises Cellartis AB

September 26, 2011

Vinge has advised the owners of Cellartis in connection with the sale of Cellartis AB to Cellectis S.A., a company listed on NYSE Euronext in Paris. The owners consist of InnovationsKapital among other venture capital investers as well as the company’s founders and employees. Cellartis has developed world-leading products based on pluripotent stem cells. Cellartis and Cellectis will jointly become a world-leading actor within R&D and development of products and services relating to regenerative and medical applications.

The purchase price consists of a cash element of € 16,400,000, and 1,930,000 in newly-issued Cellectis shares.

Vinge’s team primarily consisted of Anders Strid, Fredrik Sonander, Michael Sterner, Johanna Björnum Nyström, Emma Kero Ljungberg and Tove Bremell.

 
   

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026